Mon, Mar 2, 2015, 3:12 AM EST - U.S. Markets open in 6 hrs 18 mins


% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

  • michaelplongo michaelplongo Mar 13, 2013 7:15 PM Flag

    Edison Investment Research raises price target

    I just viewed a 16 page research report on ASTX dated March 11. Pretty good info with competitors and their progress listed. It starts out:
    Astex’s investment case has advanced considerably in recent months with its significant expansion of studies with its second-generation hypomethylating agent SGI-110, and it Hsp90 inhibitor AT13387. Astex now has six Phase I/II studies underway with these two focus products and should present final results from the first – a Phase I/II study of SGI-110 in MDS/AML – at ASH. We have revised our valuation to reflect these developments and now indicate a value of $599m, equivalent to $6.42/share basic or $5.50/diluted share.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
8.4950.0000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.